An APC genetic test looks for inherited harmful variants in the APC gene, the main cause of familial adenomatous polyposis. Familial adenomatous polyposis, or FAP, leads to many adenomatous polyps in the colon and rectum, often beginning during adolescence. Without effective surveillance and preventive treatment, classic FAP carries a very high likelihood of colorectal cancer. A milder form, attenuated FAP, usually causes fewer polyps and later cancer.
Testing can confirm the diagnosis, identify relatives who need early colon screening, and spare relatives who did not inherit the family variant from FAP-specific surveillance. It is usually performed on blood or saliva and should include methods that detect both small sequence variants and larger deletions or duplications. A positive result does not predict the exact age when polyps or cancer will occur, and a negative result does not always exclude hereditary polyposis. Results are most useful when interpreted with colonoscopy findings, personal history, family history, and genetic counseling.
- A pathogenic or likely pathogenic APC variant can confirm APC-associated polyposis and usually means each child has a 50% chance of inheriting it.
- Classic FAP often causes hundreds to thousands of colorectal adenomas, while attenuated FAP may cause fewer than 100 and can appear later.
- A negative APC result does not rule out polyposis when testing was incomplete, mosaicism is present, or another gene is responsible.
- Testing usually uses blood or saliva and requires no fasting, but a positive result should lead to a personalized surveillance and surgical plan.
- A variant of uncertain significance should not be used by itself for preventive surgery or predictive testing of healthy relatives.
Table of Contents
- What the APC Gene Does
- Who Should Consider APC Testing
- How the Test Is Performed
- APC Test Results Explained
- Cancer Risks and Health Effects
- Surveillance and Treatment After a Positive Result
- Family Testing and Reproductive Options
- Limits of APC Testing
What the APC Gene Does
APC is a tumor-suppressor gene. Its protein helps regulate the Wnt signaling pathway, controls how cells attach and divide, and supports normal chromosome separation. When both working copies of APC are lost in a colon cell, growth signals can remain active and an adenomatous polyp can form. Additional genetic changes may then allow a polyp to become cancerous.
A person with FAP is born with one altered APC copy in most or all cells. This is a germline variant. A second change can occur later in individual colon cells, leading to repeated polyp formation. This two-step process helps explain why a single inherited variant can produce hundreds of separate adenomas.
APC-associated conditions include:
- Classic FAP: usually hundreds to thousands of colorectal adenomas, often beginning in the teenage years.
- Attenuated FAP: generally fewer adenomas, later onset, and a tendency toward right-sided colon polyps.
- Gastric adenocarcinoma and proximal polyposis of the stomach: a rare APC-related condition caused by specific promoter variants and characterized mainly by stomach polyposis rather than colorectal polyposis.
Older names such as Gardner syndrome and Turcot syndrome may describe particular feature combinations, but they are not separate APC genes. Gardner syndrome historically referred to FAP with findings such as desmoid tumors, osteomas, epidermoid cysts, and dental abnormalities. Some APC carriers also develop specific brain tumors, particularly medulloblastoma.
Most pathogenic APC variants cause a shortened, nonworking protein. Large deletions involving one or more exons can also cause disease. The exact location of a variant may influence the average severity, but genotype–phenotype correlations are not precise enough to replace colonoscopy findings. Even relatives with the same variant can have different polyp numbers and ages of onset.
The inheritance pattern is autosomal dominant. A person with a germline pathogenic APC variant has a 50% chance of passing it to each child, regardless of sex. About one quarter of affected people may have a new variant that was not inherited from either parent. Some have mosaicism, meaning the variant is present in only a fraction of cells; this can make blood testing and family-risk estimates more complicated.
Who Should Consider APC Testing
Testing is considered when a person’s polyp burden, cancer history, or family history suggests an adenomatous polyposis syndrome. A clinician may recommend a hereditary cancer genetic panel rather than APC-only testing because several genes can cause overlapping findings.
Common reasons for evaluation include:
- Dozens to hundreds of adenomatous colorectal polyps
- Colorectal polyps beginning in childhood, adolescence, or early adulthood
- Colorectal cancer plus multiple adenomas
- A close relative with FAP, attenuated FAP, or a known APC pathogenic variant
- Duodenal or ampullary adenomas with colorectal polyposis
- Desmoid tumors, especially with a personal or family history of polyps
- Congenital hypertrophy of the retinal pigment epithelium in a suggestive family
- Multiple osteomas, epidermoid cysts, or characteristic dental findings with polyposis
- A childhood hepatoblastoma or certain medulloblastomas in a family with APC-related disease
When a family variant is already known, healthy relatives can have a focused targeted variant test. This is faster and easier to interpret than repeating a broad panel. Predictive testing is often offered during childhood because colon surveillance for classic FAP generally begins in early adolescence. Testing a child for an adult-onset condition is often delayed, but FAP is different because medical management starts before adulthood.
The best first person to test is usually an affected family member with the clearest polyposis diagnosis. If that person has a pathogenic APC variant, other relatives can be tested for the same change. Starting with an unaffected relative can produce an uninformative negative result if the family’s cause has never been identified.
Testing should not be based only on a family’s number of colorectal cancers. Lynch syndrome, MUTYH-associated polyposis, polymerase-proofreading-associated polyposis, and other conditions can resemble APC-associated disease. Pathology records showing the number and type of polyps are especially useful. Adenomas differ from hamartomatous, serrated, and inflammatory polyps, which point toward other diagnoses.
How the Test Is Performed
APC germline testing usually requires a blood sample, saliva sample, or cheek swab. Blood often provides the most consistent DNA quality, but saliva is acceptable for many laboratories. No fasting is needed. The laboratory analyzes DNA from normal cells, not tumor tissue, because the question is whether the variant is inherited and present throughout the body.
A complete APC test should generally include:
- Sequence analysis to identify single-letter DNA changes and small insertions or deletions.
- Deletion and duplication analysis to detect one or more missing or extra exons or a deletion of the entire gene.
- Promoter analysis when clinically relevant, particularly for gastric adenocarcinoma and proximal polyposis of the stomach.
- Mosaicism assessment when the phenotype is convincing but routine blood testing is negative.
Many laboratories use next-generation sequencing, followed by confirmation of important findings. A deletion and duplication test may use methods such as multiplex ligation-dependent probe amplification or read-depth analysis. Reports should state which regions were covered and whether promoter variants, deep intronic changes, and low-level mosaicism were assessed.
A multigene panel may include APC, MUTYH, POLE, POLD1, NTHL1, MSH3, AXIN2, GREM1, and genes linked to other gastrointestinal polyposis syndromes. Panel testing increases the chance of finding the correct cause but also increases the chance of a variant of uncertain significance.
Results often take two to six weeks, although targeted family testing may be faster. The laboratory sends a report to the ordering clinician. Pretest and post-test genetic counseling can clarify possible results, insurance considerations, privacy, family implications, and how testing may affect children.
Mosaic APC testing deserves special attention. If a pathogenic variant arose after conception, it may be absent or present at a very low level in blood. Testing adenoma tissue, normal colon tissue, skin-derived cells, or more than one tissue type may be considered by a specialized genetics team. Finding the same APC variant in multiple separate adenomas can support mosaicism, but tumor-only findings must be interpreted carefully because ordinary colorectal tumors often acquire somatic APC mutations.
APC Test Results Explained
Pathogenic or likely pathogenic
A pathogenic or likely pathogenic germline APC variant is considered disease-causing. In a person with polyposis, it confirms APC-associated polyposis. In an unaffected relative, it shows that FAP surveillance is needed even if the first colon examination is normal.
“Likely pathogenic” generally means the laboratory has strong evidence that the variant causes disease, although the evidence is not quite sufficient for the highest category. Medical management is usually the same as for a pathogenic result. The report may also include the DNA and protein notation, exon, classification evidence, and associated phenotype.
A positive result does not determine the exact number of future polyps, the timing of surgery, or the certainty of every extracolonic complication. Those decisions depend on endoscopy, pathology, symptoms, family history, and personal circumstances.
Negative
A negative result means no reportable disease-causing APC variant was detected by that test. Its meaning depends on context.
If the person was tested only for a known family variant and the result is negative, that person usually did not inherit the family’s APC-associated risk. FAP-specific surveillance can often be stopped, although ordinary population screening and care for any independent symptoms still apply.
If the person has extensive polyposis but no family variant is known, a negative result is uninformative. Possible explanations include another polyposis gene, mosaic APC disease, an alteration the assay cannot detect, or a nonhereditary cause. Clinical surveillance should continue based on the phenotype. Negative genetic testing should never be used to dismiss hundreds of adenomas.
Variant of uncertain significance
A variant of uncertain significance, or VUS, is a DNA change whose effect is not known. It is not a positive diagnosis. A VUS should not by itself trigger colectomy, alter screening for relatives, or be used for predictive testing in healthy family members. Management should follow the person’s polyps and family history while the laboratory gathers more evidence.
VUS classifications can change. The ordering clinic should have a plan for amended reports. Patients should not rely on crowd-sourced variant databases or interpret a VUS as “probably harmful” without expert review.
Benign or likely benign
These variants do not explain FAP and usually are not highlighted in a clinical report. One specific APC change, p.Ile1307Lys, is a moderate-risk allele seen more often in people of Ashkenazi Jewish ancestry. It does not cause classic FAP and should not be interpreted like a truncating pathogenic APC variant. Recommendations depend on ancestry, family history, and current guidelines.
Cancer Risks and Health Effects
Classic FAP is defined by a very high colorectal polyp burden and, without preventive management, a near-certainty of colorectal cancer over a lifetime. Polyps often begin around puberty, and cancer can occur in early adulthood. Attenuated FAP generally carries a lower but still substantial colorectal cancer risk, often with later onset.
APC-associated disease can affect more than the colon. Important findings include: **Health concerns associated with pathogenic APC variants**
| Organ or condition | Typical concern | How it is followed |
|---|---|---|
| Colon and rectum | Numerous adenomas and colorectal cancer | Regular lower endoscopy and planned preventive surgery |
| Duodenum and ampulla | Adenomas and increased cancer risk | Upper endoscopy with careful duodenal and ampullary inspection |
| Stomach | Fundic gland polyps, adenomas, and selected gastric cancer risks | Upper endoscopy with targeted biopsy or removal |
| Thyroid | Papillary thyroid cancer, often cribriform-morular type | Neck examination and ultrasound according to the care plan |
| Abdominal wall or mesentery | Desmoid tumors that can grow aggressively despite being nonmetastatic | Clinical assessment and imaging when indicated |
| Childhood liver | Hepatoblastoma risk in young children | Family-specific discussion of early-childhood surveillance |
Desmoid tumors require nuanced care. They do not spread to distant organs like cancer, but they can invade locally, compress the bowel or ureters, and complicate abdominal surgery. Risk varies with family history, sex, prior surgery, and variant location. Surgery is not automatically the first treatment for every desmoid because operations can cause morbidity or stimulate recurrence.
Some physical findings, such as jaw osteomas, dental abnormalities, epidermoid cysts, and retinal pigment changes, can provide diagnostic clues but do not determine cancer risk by themselves. Their absence does not rule out FAP.
Surveillance and Treatment After a Positive Result
A positive APC result leads to lifelong, organ-specific care. The schedule should be created by clinicians experienced in hereditary gastrointestinal cancer and adjusted for phenotype.
For classic FAP, lower gastrointestinal surveillance commonly begins around ages 10 to 15, using colonoscopy or, in selected settings, flexible sigmoidoscopy. Once adenomas appear, examinations are usually repeated every one to two years or more often when the burden rises. In attenuated FAP, full colonoscopy is essential because polyps often cluster in the proximal colon.
Endoscopy can delay surgery when the number, size, and pathology of polyps remain manageable, but it cannot safely control classic FAP indefinitely. Preventive colorectal surgery is considered when polyps are too numerous to remove, large or high-grade lesions appear, cancer is suspected, symptoms develop, or surveillance becomes unreliable.
Common operations include total colectomy with ileorectal anastomosis and proctocolectomy with ileal pouch–anal anastomosis. The choice depends on rectal polyp burden, cancer, age, fertility plans, continence, desmoid risk, and willingness to continue rectal surveillance. Surgery removes much of the colorectal cancer risk but does not cure the genetic condition. Remaining rectal tissue, an ileal pouch, and the upper gastrointestinal tract still require surveillance.
Upper endoscopy generally begins in early adulthood and is repeated according to duodenal and gastric findings. Clinicians may use the Spigelman stage to grade duodenal polyposis, although the ampulla requires separate attention. Advanced polyposis may need endoscopic treatment or surgery at a specialized center.
Medications such as nonsteroidal anti-inflammatory drugs can reduce polyp number or size in some settings, but chemoprevention does not replace endoscopy or indicated surgery. Treatment should be supervised because these drugs can cause gastrointestinal, kidney, or cardiovascular harm.
A positive result also supports review of thyroid surveillance, desmoid symptoms, and childhood hepatoblastoma considerations. The plan should be written clearly and updated after major surgery, new pathology, pregnancy, or changes in family history.
Family Testing and Reproductive Options
Once a pathogenic APC variant is identified, first-degree relatives—parents, siblings, and children—each may have a 50% chance of carrying it. Cascade testing allows relatives to learn their status before polyps become advanced. A negative targeted test in a relative can remove the need for intensive FAP surveillance, while a positive result allows screening to begin on time.
If neither parent carries the variant in blood, the affected person may have a new variant. Germline mosaicism in a parent is uncommon but possible, so recurrence risk is not always exactly zero. The affected person can still pass the variant to children with a 50% chance.
Adults planning a family may discuss natural conception with prenatal testing, in vitro fertilization with preimplantation genetic testing, donor eggs or sperm, adoption, or choosing not to test during pregnancy. These are personal choices. A genetics professional can explain timing, accuracy, cost, and ethical considerations without directing the decision.
Because predictive testing affects minors, counseling should include age-appropriate assent, privacy, emotional support, and a clear surveillance plan. Testing should not be performed simply to satisfy curiosity; it should connect to care that can benefit the child.
Limits of APC Testing
No genetic test detects every possible cause of polyposis. Routine sequencing may miss deep intronic variants, complex rearrangements, promoter changes outside the assay, or low-level mosaicism. Laboratories also differ in coverage and classification. The test report’s methods and limitations are therefore clinically important.
A positive APC result does not replace colonoscopy. A negative result does not replace clinical care when dozens of adenomas are present. A VUS does not establish a diagnosis. Tumor-only APC mutations are common in ordinary colorectal cancers and should not be assumed to be inherited without testing a normal sample.
Questions to ask include:
- Was sequencing plus deletion and duplication analysis performed?
- Did the assay assess mosaicism or APC promoter regions?
- Should a multigene panel be considered?
- Is the result germline, tumor-only, or uncertain?
- When should colon and upper gastrointestinal surveillance begin?
- What findings would prompt surgery?
- Which relatives should be offered targeted testing?
- Will the laboratory notify the clinic if a variant is reclassified?
Urgent evaluation is needed for heavy rectal bleeding, severe abdominal pain, persistent vomiting, bowel obstruction symptoms, or rapid abdominal enlargement. Routine follow-up should address changes in bowel habits, anemia, unexplained weight loss, or new abdominal masses promptly rather than waiting for the next scheduled endoscopy.
How clinical findings and the variant work together
Clinicians do not choose surveillance or surgery from the gene result alone. They combine the genotype with the number, size, location, and microscopic features of polyps; the presence of cancer; the condition of the rectum; upper gastrointestinal findings; and the person’s ability to return for frequent procedures. A variant associated on average with attenuated disease can still occur in someone with a heavy polyp burden, and a “classic” region variant does not prove that a young carrier already needs surgery.
Records from relatives can sharpen interpretation. Ages at colectomy, colorectal cancer diagnoses, desmoid tumors, and duodenal disease may reveal a family pattern, but variation within one family remains common. Management should therefore be individualized for each carrier rather than copied automatically from a parent or sibling.
After any major procedure, the surveillance plan should state exactly which tissue remains. Someone with an ileorectal anastomosis needs careful rectal examinations. Someone with an ileal pouch needs pouch and anal-transition-zone surveillance. A person with a permanent ileostomy still needs upper gastrointestinal and other extracolonic follow-up. Keeping the genetic report, operative note, pathology reports, and latest endoscopy findings together helps new clinicians understand the current risk and avoid repeating tests or missing required surveillance after transitions in care between pediatric, adult, surgical, and community teams.
References
- APC-Associated Polyposis Conditions 2022 (Review)
- Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision 2024 (Guideline)
- Management of Inherited Adenomatous Polyposis Syndromes (2024) 2025 (Guideline)
- Screening and surveillance for hereditary colorectal cancer 2024 (Review)
- Guidelines for Familial Adenomatous Polyposis (FAP): challenges in defining clinical management for a rare disease 2025 (Review)
- Familial adenomatous polyposis: non-surgical management of a challenging disease 2025 (Review)
Disclaimer
This article is for education and does not replace care from a gastroenterologist, colorectal surgeon, or genetics professional. APC results and surveillance schedules must be individualized according to the exact variant, polyp burden, pathology, family history, age, and prior surgery. Seek prompt medical care for severe bleeding, obstruction symptoms, or acute abdominal pain.
